Symbols / IMVT
IMVT Chart
About
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.81B |
| Enterprise Value | 4.58B | Income | -464.20M | Sales | — |
| Book/sh | 4.85 | Cash/sh | 4.89 | Dividend Yield | — |
| Payout | 0.00% | Employees | 362 | IPO | — |
| P/E | — | Forward P/E | -10.79 | PEG | — |
| P/S | — | P/B | 5.88 | P/C | — |
| EV/EBITDA | -9.41 | EV/Sales | — | Quick Ratio | 15.04 |
| Current Ratio | 15.74 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.67 | EPS next Y | -2.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-06 | ROA | -41.33% |
| ROE | -69.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 203.53M |
| Shs Float | 77.49M | Short Float | 18.57% | Short Ratio | 11.10 |
| Short Interest | — | 52W High | 29.25 | 52W Low | 12.72 |
| Beta | 0.62 | Avg Volume | 1.62M | Volume | 362.51K |
| Target Price | $41.12 | Recom | Buy | Prev Close | $27.39 |
| Price | $28.54 | Change | 4.18% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$41.13
Mean price target
2. Current target
$28.54
Latest analyst target
3. DCF / Fair value
$-23.05
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.54
Low
$22.00
High
$57.00
Mean
$41.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2026-02-09 | main | Guggenheim | Buy → Buy | $44 |
| 2026-01-08 | main | Truist Securities | Hold → Hold | $22 |
| 2026-01-06 | up | Wolfe Research | Peer Perform → Outperform | $50 |
| 2025-12-15 | main | Goldman Sachs | Neutral → Neutral | $28 |
| 2025-10-14 | init | Truist Securities | — → Hold | $16 |
| 2025-09-30 | main | JP Morgan | Overweight → Overweight | $33 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-08-12 | main | JP Morgan | Overweight → Overweight | $37 |
| 2025-08-12 | main | B of A Securities | Buy → Buy | $30 |
| 2025-07-28 | main | UBS | Neutral → Neutral | $18 |
| 2025-04-22 | down | UBS | Buy → Neutral | $17 |
| 2025-03-20 | reit | Guggenheim | Buy → Buy | — |
| 2025-03-20 | main | B of A Securities | Buy → Buy | $33 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
| 2025-03-10 | reit | Guggenheim | Buy → Buy | — |
| 2025-02-10 | main | Guggenheim | Buy → Buy | $44 |
| 2025-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
| 2025-01-15 | main | B of A Securities | Buy → Buy | $45 |
- Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return - Yahoo Finance Mon, 23 Feb 2026 04
- IMMUNOVANT ($IMVT) Releases Q3 2026 Earnings - Quiver Quantitative Fri, 06 Feb 2026 08
- Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves’ launch - Stock Titan hu, 11 Dec 2025 08
- Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com Fri, 12 Dec 2025 08
- IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Nasdaq Mon, 09 Feb 2026 08
- Does Immunovant’s (IMVT) Narrower Quarterly Per‑Share Loss Reframe Its Long‑Term Risk‑Reward Equation? - simplywall.st Sat, 07 Feb 2026 08
- Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance ue, 02 Dec 2025 08
- $IMVT stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 27 Oct 2025 07
- Immunovant (NASDAQ: IMVT) cash runway to 2027; TED Phase III topline H1 2026 - Stock Titan Mon, 10 Nov 2025 08
- Immunovant CTO Stout sells $32k in IMVT stock - Investing.com Fri, 09 Jan 2026 08
- How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Yahoo Finance hu, 15 Jan 2026 08
- IMMUNOVANT Earnings Preview: Recent $IMVT Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 29 Oct 2025 07
- A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance Sat, 07 Feb 2026 08
- IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - Yahoo Finance hu, 04 Sep 2025 07
- Where is Immunovant (IMVT) Heading According to Analysts? - Yahoo Finance ue, 30 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1977 | 51461 | — | Sale at price 26.03 per share. | STOUT JAY S | Chief Technology Officer | — | 2026-01-21 00:00:00 | D |
| 1 | 1203 | 31914 | — | Sale at price 26.51 - 26.92 per share. | STOUT JAY S | Chief Technology Officer | — | 2026-01-07 00:00:00 | D |
| 2 | 10813 | 290943 | — | Sale at price 26.78 - 27.38 per share. | VAN TUYL CHRISTOPHER | Officer | — | 2025-12-18 00:00:00 | D |
| 3 | 16666666 | 440333316 | — | Purchase at price 26.42 per share. | ROIVANT SCIENCES LTD. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-12 00:00:00 | D |
| 4 | 15000 | 348665 | — | Sale at price 23.14 - 23.96 per share. | HUGHES DOUGLAS J | Director | — | 2025-12-01 00:00:00 | D |
| 5 | 22249 | 517189 | — | Sale at price 23.14 - 23.95 per share. | FROMKIN ANDREW J | Director | — | 2025-12-01 00:00:00 | D |
| 6 | 12626 | 298237 | — | Sale at price 23.54 - 23.97 per share. | GLORIA MELANIE | Chief Operating Officer | — | 2025-11-20 00:00:00 | D |
| 7 | 2520 | 47956 | — | Sale at price 19.03 per share. | STOUT JAY S | Chief Technology Officer | — | 2025-10-22 00:00:00 | D |
| 8 | 2595 | 49383 | — | Sale at price 19.03 per share. | GEFFNER MICHAEL | Officer | — | 2025-10-22 00:00:00 | D |
| 9 | 1585 | 25836 | — | Sale at price 16.30 per share. | STOUT JAY S | Chief Technology Officer | — | 2025-10-08 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -2.62M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -437.77M | -257.48M | -198.08M | -155.91M |
| TotalUnusualItems | 0.00 | -12.50M | -10.00M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -12.50M | -10.00M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -413.84M | -259.34M | -210.96M | -156.73M |
| ReconciledDepreciation | 377.00K | 231.00K | 193.00K | 126.00K |
| EBITDA | -437.77M | -269.98M | -208.08M | -155.91M |
| EBIT | -438.15M | -270.21M | -208.28M | -156.03M |
| NetInterestIncome | 24.73M | 24.95M | 7.58M | 0.00 |
| InterestExpense | 0.00 | |||
| InterestIncome | 24.73M | 24.95M | 7.58M | 0.00 |
| NormalizedIncome | -413.84M | -249.46M | -200.96M | -156.73M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -413.84M | -259.34M | -210.96M | -156.73M |
| TotalExpenses | 438.15M | 270.21M | 208.28M | 156.03M |
| DilutedAverageShares | 151.57M | 138.10M | 123.08M | 109.68M |
| BasicAverageShares | 151.57M | 138.10M | 123.08M | 109.68M |
| DilutedEPS | -2.73 | -1.88 | -1.71 | -1.43 |
| BasicEPS | -2.73 | -1.88 | -1.71 | -1.43 |
| DilutedNIAvailtoComStockholders | -413.84M | -259.34M | -210.96M | -156.73M |
| NetIncomeCommonStockholders | -413.84M | -259.34M | -210.96M | -156.73M |
| NetIncome | -413.84M | -259.34M | -210.96M | -156.73M |
| NetIncomeIncludingNoncontrollingInterests | -413.84M | -259.34M | -210.96M | -156.73M |
| NetIncomeContinuousOperations | -413.84M | -259.34M | -210.96M | -156.73M |
| TaxProvision | 891.00K | 567.00K | 9.00K | -84.00K |
| PretaxIncome | -412.95M | -258.77M | -210.95M | -156.81M |
| OtherIncomeExpense | 471.00K | -13.51M | -10.25M | -781.00K |
| OtherNonOperatingIncomeExpenses | 471.00K | -1.01M | -253.00K | -781.00K |
| SpecialIncomeCharges | 0.00 | -12.50M | -10.00M | 0.00 |
| OtherSpecialCharges | 12.50M | 10.00M | ||
| RestructuringAndMergernAcquisition | 0.00 | 12.50M | 10.00M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 24.73M | 24.95M | 7.58M | 0.00 |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 24.73M | 24.95M | 7.58M | 0.00 |
| OperatingIncome | -438.15M | -270.21M | -208.28M | -156.03M |
| OperatingExpense | 438.15M | 270.21M | 208.28M | 156.03M |
| ResearchAndDevelopment | 360.92M | 212.93M | 160.26M | 101.81M |
| SellingGeneralAndAdministration | 77.23M | 57.28M | 48.02M | 54.23M |
| GeneralAndAdministrativeExpense | 77.23M | 57.28M | 48.02M | 54.23M |
| OtherGandA | 77.23M | 57.28M | 48.02M | 54.23M |
| SalariesAndWages | 11.79M | |||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| PreferredSharesNumber | 10.00K | 10.00K | 10.00K | 10.00K |
| OrdinarySharesNumber | 170.11M | 145.58M | 130.33M | 116.48M |
| ShareIssued | 170.11M | 145.58M | 130.33M | 116.48M |
| TotalDebt | 98.00K | 138.00K | 1.22M | 2.36M |
| TangibleBookValue | 707.45M | 617.76M | 362.49M | 469.82M |
| InvestedCapital | 707.45M | 617.76M | 362.49M | 469.82M |
| WorkingCapital | 698.89M | 617.16M | 361.04M | 468.41M |
| NetTangibleAssets | 707.45M | 617.76M | 362.49M | 469.82M |
| CapitalLeaseObligations | 98.00K | 138.00K | 1.22M | 2.36M |
| CommonStockEquity | 707.45M | 617.76M | 362.49M | 469.82M |
| TotalCapitalization | 707.45M | 617.76M | 362.49M | 469.82M |
| TotalEquityGrossMinorityInterest | 707.45M | 617.76M | 362.49M | 469.82M |
| StockholdersEquity | 707.45M | 617.76M | 362.49M | 469.82M |
| GainsLossesNotAffectingRetainedEarnings | 1.46M | 1.91M | 852.00K | 404.00K |
| OtherEquityAdjustments | 1.46M | 1.91M | 852.00K | 404.00K |
| RetainedEarnings | -1.24B | -825.68M | -566.35M | -355.39M |
| AdditionalPaidInCapital | 1.95B | 1.44B | 927.98M | 824.80M |
| CapitalStock | 16.00K | 14.00K | 13.00K | 12.00K |
| CommonStock | 16.00K | 14.00K | 13.00K | 12.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 68.78M | 48.61M | 43.34M | 45.74M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 47.00K | 1.22M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 47.00K | 1.22M | 2.24M |
| LongTermCapitalLeaseObligation | 0.00 | 47.00K | 1.22M | 2.24M |
| CurrentLiabilities | 68.78M | 48.61M | 43.30M | 44.52M |
| CurrentDebtAndCapitalLeaseObligation | 98.00K | 138.00K | 1.17M | 1.15M |
| CurrentCapitalLeaseObligation | 98.00K | 138.00K | 1.17M | 1.15M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 15.62M | 14.74M | 7.53M | 4.46M |
| PayablesAndAccruedExpenses | 53.06M | 33.73M | 34.59M | 38.92M |
| CurrentAccruedExpenses | 35.13M | 26.56M | 32.89M | 20.12M |
| Payables | 17.93M | 7.17M | 1.70M | 18.80M |
| DuetoRelatedPartiesCurrent | 273.00K | 15.00K | 350.00K | 171.00K |
| AccountsPayable | 17.66M | 7.16M | 1.35M | 18.63M |
| TotalAssets | 776.22M | 666.37M | 405.84M | 515.56M |
| TotalNonCurrentAssets | 8.56M | 595.00K | 1.50M | 2.63M |
| OtherNonCurrentAssets | 7.62M | |||
| NonCurrentDeferredAssets | 0.00 | |||
| NetPPE | 942.00K | 595.00K | 1.50M | 2.63M |
| GrossPPE | 942.00K | 595.00K | 1.50M | 2.63M |
| OtherProperties | 942.00K | 595.00K | 1.50M | 2.63M |
| BuildingsAndImprovements | 3.28M | |||
| Properties | 0.00 | |||
| CurrentAssets | 767.66M | 665.77M | 404.33M | 512.93M |
| OtherCurrentAssets | 51.18M | 24.90M | 26.92M | 6.25M |
| PrepaidAssets | 6.25M | 7.72M | ||
| Receivables | 2.51M | 5.50M | 885.00K | 12.86M |
| TaxesReceivable | 427.00K | 166.00K | 185.00K | 632.00K |
| AccountsReceivable | 2.08M | 5.34M | 700.00K | 12.23M |
| CashCashEquivalentsAndShortTermInvestments | 713.97M | 635.37M | 376.53M | 493.82M |
| CashAndCashEquivalents | 713.97M | 635.37M | 376.53M | 493.82M |
| CashFinancial | 493.82M | 400.15M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -376.63M | -214.59M | -188.39M | -106.37M |
| RepaymentOfDebt | 0.00 | -3.19M | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 450.00M | 472.75M | 70.50M | 0.00 |
| CapitalExpenditure | -759.00K | -360.00K | -197.00K | -254.00K |
| IncomeTaxPaidSupplementalData | 1.20M | 509.00K | 0.00 | 0.00 |
| EndCashPosition | 713.97M | 635.37M | 376.53M | 493.82M |
| BeginningCashPosition | 635.37M | 376.53M | 493.82M | 400.15M |
| EffectOfExchangeRateChanges | 747.00K | 993.00K | 220.00K | -92.00K |
| ChangesInCash | 77.86M | 257.84M | -117.50M | 93.76M |
| FinancingCashFlow | 454.49M | 472.43M | 70.89M | 200.13M |
| CashFlowFromContinuingFinancingActivities | 454.49M | 472.43M | 70.89M | 200.13M |
| NetOtherFinancingCharges | -319.00K | -6.01M | -272.00K | 200.13M |
| ProceedsFromStockOptionExercised | 4.81M | 5.69M | 657.00K | 0.00 |
| NetCommonStockIssuance | 450.00M | 472.75M | 70.50M | 0.00 |
| CommonStockIssuance | 450.00M | 472.75M | 70.50M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | -3.19M | ||
| NetShortTermDebtIssuance | -3.19M | |||
| ShortTermDebtPayments | -3.19M | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | -3.19M | ||
| LongTermDebtPayments | 0.00 | -3.19M | ||
| InvestingCashFlow | -759.00K | -360.00K | -197.00K | -254.00K |
| CashFlowFromContinuingInvestingActivities | -759.00K | -360.00K | -197.00K | -254.00K |
| NetPPEPurchaseAndSale | -759.00K | -360.00K | -197.00K | -254.00K |
| PurchaseOfPPE | -759.00K | -360.00K | -197.00K | -254.00K |
| OperatingCashFlow | -375.87M | -214.23M | -188.19M | -106.11M |
| CashFlowFromContinuingOperatingActivities | -375.87M | -214.23M | -188.19M | -106.11M |
| ChangeInWorkingCapital | -12.03M | 2.63M | -10.85M | 15.14M |
| ChangeInOtherCurrentLiabilities | -138.00K | -1.17M | -1.15M | -1.18M |
| ChangeInOtherCurrentAssets | -7.74M | 0.00 | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 19.86M | 6.80M | -1.40M | 25.90M |
| ChangeInAccruedExpense | 8.92M | 1.35M | 15.57M | 9.47M |
| ChangeInPayable | 10.94M | 5.46M | -16.97M | 16.43M |
| ChangeInAccountPayable | 10.68M | 5.78M | -17.12M | 16.25M |
| ChangeInPrepaidAssets | -26.99M | 1.56M | -20.53M | 2.14M |
| ChangeInReceivables | 2.97M | -4.56M | 12.22M | -11.72M |
| ChangesInAccountReceivables | 3.23M | -4.58M | 11.76M | -11.63M |
| OtherNonCashItems | 133.00K | 1.13M | 1.13M | 1.11M |
| StockBasedCompensation | 49.49M | 41.12M | 32.30M | 34.24M |
| AssetImpairmentCharge | 0.00 | |||
| DepreciationAmortizationDepletion | 377.00K | 231.00K | 193.00K | 126.00K |
| DepreciationAndAmortization | 377.00K | 231.00K | 193.00K | 126.00K |
| Depreciation | 377.00K | 231.00K | 193.00K | 126.00K |
| OperatingGainsLosses | -282.00K | |||
| NetForeignCurrencyExchangeGainLoss | -282.00K | |||
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -413.84M | -259.34M | -210.96M | -156.73M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IMVT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|